AU2018358138C1 - Bispecific antibodies and methods of making and using thereof - Google Patents

Bispecific antibodies and methods of making and using thereof Download PDF

Info

Publication number
AU2018358138C1
AU2018358138C1 AU2018358138A AU2018358138A AU2018358138C1 AU 2018358138 C1 AU2018358138 C1 AU 2018358138C1 AU 2018358138 A AU2018358138 A AU 2018358138A AU 2018358138 A AU2018358138 A AU 2018358138A AU 2018358138 C1 AU2018358138 C1 AU 2018358138C1
Authority
AU
Australia
Prior art keywords
ser
gly
val
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018358138A
Other languages
English (en)
Other versions
AU2018358138A1 (en
AU2018358138B2 (en
Inventor
Bill Brady
Katrina BYKOVA
Jonathan K. FALLON
Zeren Gao
Brian Kovacevich
Blair RENSHAW
Phil TAN
Dong Xia
Yi Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Systimmune Inc
Original Assignee
Systimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systimmune Inc filed Critical Systimmune Inc
Publication of AU2018358138A1 publication Critical patent/AU2018358138A1/en
Publication of AU2018358138B2 publication Critical patent/AU2018358138B2/en
Assigned to SYSTIMMUNE, INC., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. reassignment SYSTIMMUNE, INC. Request for Assignment Assignors: SICHUAN BAILI PHARMACEUTICAL CO. LTD., SYSTIMMUNE, INC.
Application granted granted Critical
Publication of AU2018358138C1 publication Critical patent/AU2018358138C1/en
Assigned to SYSTIMMUNE, INC. reassignment SYSTIMMUNE, INC. Request for Assignment Assignors: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd., SYSTIMMUNE, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2018358138A 2017-11-02 2018-11-01 Bispecific antibodies and methods of making and using thereof Active AU2018358138C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762580845P 2017-11-02 2017-11-02
US62/580,845 2017-11-02
PCT/US2018/058810 WO2019090002A1 (en) 2017-11-02 2018-11-01 Bispecific antibodies and methods of making and using thereof

Publications (3)

Publication Number Publication Date
AU2018358138A1 AU2018358138A1 (en) 2020-04-23
AU2018358138B2 AU2018358138B2 (en) 2022-06-02
AU2018358138C1 true AU2018358138C1 (en) 2022-12-08

Family

ID=66332369

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018358138A Active AU2018358138C1 (en) 2017-11-02 2018-11-01 Bispecific antibodies and methods of making and using thereof

Country Status (11)

Country Link
US (1) US20200347137A1 (enExample)
EP (1) EP3703736A4 (enExample)
JP (1) JP7418326B2 (enExample)
KR (2) KR102785809B1 (enExample)
CN (2) CN117343193A (enExample)
AU (1) AU2018358138C1 (enExample)
CA (1) CA3069238A1 (enExample)
IL (1) IL271346A (enExample)
SG (1) SG11202003237QA (enExample)
TW (1) TWI896517B (enExample)
WO (1) WO2019090002A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7383605B2 (ja) * 2017-06-25 2023-11-20 システィミューン， インク． 抗ｐｄ－ｌ１抗体とその作製及び使用方法
US12649792B2 (en) 2019-05-06 2026-06-09 Brown University Bispecific antibodies against CHI3L1 and PD1 with enhanced T cell-mediated cytotoxic effects on tumor cells
EP4061849A4 (en) * 2019-11-21 2024-05-29 Brown University BISPECIFIC ANTIBODIES AGAINST CHI3L1 AND CTLA4 WITH IMPROVED CYTOTOXIC EFFECTS ON TUMOR CELLS
EP4069746A4 (en) * 2019-12-04 2023-12-27 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. BISPECIFIC FUSION PROTEIN FOR TUMOR TREATMENT
TW202511295A (zh) * 2023-08-31 2025-03-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｔｌａ４／ｔｉｇｉｔ結合蛋白及其醫藥用途
CN122161858A (zh) * 2023-09-18 2026-06-05 翰思艾泰生物医药科技(武汉)股份有限公司 靶向ctla4和cd47的抗体及其用途
WO2026061422A1 (en) * 2024-09-18 2026-03-26 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Methods for treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105338A2 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
US20070281334A1 (en) * 2002-03-29 2007-12-06 Xoma Technology Ltd. Methods and materials for increasing expression of recombinant polypeptides
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399618B2 (en) * 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
JP2008537941A (ja) 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
EP3683314A1 (en) * 2013-10-07 2020-07-22 Prestige Biopharma Pte. Ltd. Bicistronic expression vector for antibody expression and method for producing antibody using same
CN104974253A (zh) 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US10717783B2 (en) * 2014-12-22 2020-07-21 Zeren Gao Bispecific tetravalent antibodies and methods of making and using thereof
US10196445B1 (en) * 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
CN104987421A (zh) 2015-05-13 2015-10-21 北京比洋生物技术有限公司 抗ctla-4和pd-1的双重可变结构域免疫球蛋白
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
AU2018366199A1 (en) * 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070281334A1 (en) * 2002-03-29 2007-12-06 Xoma Technology Ltd. Methods and materials for increasing expression of recombinant polypeptides
WO2006105338A2 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LUSSIER et al., "Combination immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma", J Immunother Cancer, (2015-05-19), vol. 3, no. 21, pages 1 - 11 *

Also Published As

Publication number Publication date
TWI896517B (zh) 2025-09-11
SG11202003237QA (en) 2020-05-28
TW201927819A (zh) 2019-07-16
US20200347137A1 (en) 2020-11-05
JP2021501575A (ja) 2021-01-21
RU2020108444A3 (enExample) 2022-03-17
CN111212658B (zh) 2024-05-03
AU2018358138A1 (en) 2020-04-23
EP3703736A4 (en) 2021-11-03
CA3069238A1 (en) 2019-05-09
NZ763370A (en) 2024-10-25
CN111212658A (zh) 2020-05-29
CN117343193A (zh) 2024-01-05
IL271346A (en) 2020-01-30
KR20250044943A (ko) 2025-04-01
KR20200091382A (ko) 2020-07-30
EP3703736A1 (en) 2020-09-09
KR102785809B1 (ko) 2025-03-26
AU2018358138B2 (en) 2022-06-02
JP7418326B2 (ja) 2024-01-19
WO2019090002A1 (en) 2019-05-09
RU2020108444A (ru) 2021-12-02

Similar Documents

Publication Publication Date Title
KR102831970B1 (ko) 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
CN110869389B (zh) 抗ror1抗体及其制备和使用方法
AU2018358138B2 (en) Bispecific antibodies and methods of making and using thereof
CN111954680B (zh) IL2Rβ/共同γ链抗体
KR102916159B1 (ko) Ilt4에 결합하는 항체
AU2024200534A1 (en) Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
DK2519543T3 (en) HETERODIMER BINDING PROTEINS AND USE THEREOF
AU2017336673B2 (en) Low-viscosity antigen binding proteins and methods of making them
AU2021254602A1 (en) Humanized anti-MUC1* antibodies
KR102230620B1 (ko) Ｃｄｈ19 및 ｃｄ3에 대한 항체 작제물
KR101459159B1 (ko) Ｏｘ-2/ｃｄ200에 대한 항체 및 이들의 용도
CN112225817B (zh) 卷曲螺旋免疫球蛋白融合蛋白及其组合物
KR20230002261A (ko) 항-sars-cov-2 중화 항체 및 이의 사용 방법
KR20220167273A (ko) 항-코로나바이러스 항체 및 사용 방법
KR20230017841A (ko) Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
KR20220154710A (ko) 소형 유도 및 항법 제어(miniGNC) 항체-유사 단백질 및 이의 제조 및 사용 방법
KR20230059789A (ko) 항-가변 muc1* 항체 및 이의 용도
KR20160021849A (ko) 렉틴-유사 산화된 ldl 수용체1 항체 및 사용 방법
KR20190123353A (ko) 폴리펩티드 구축물 및 이의 용도
KR20230017815A (ko) 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
KR20230027300A (ko) Il-10 뮤테인 및 이의 융합 단백질
CN113316587B (zh) 一种双特异性分子及其制备与用途
RU2787783C2 (ru) Биспецифические антитела и способы их получения и применения
HK40019735A (en) Bispecific antibodies and methods of making and using thereof
RU2838544C1 (ru) МИНИАТЮРНЫЕ АНТИТЕЛОПОДОБНЫЕ БЕЛКИ УПРАВЛЕНИЯ И НАВИГАЦИОННОГО КОНТРОЛЯ (miniGNC) И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 MAY 2022

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 27 MAY 2022

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 AUG 2022

PC1 Assignment before grant (sect. 113)

Owner name: SYSTIMMUNE, INC.

Free format text: FORMER APPLICANT(S): SYSTIMMUNE, INC.; SICHUAN BAILI PHARMACEUTICAL CO. LTD.

Owner name: BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.

Free format text: FORMER APPLICANT(S): SYSTIMMUNE, INC.; SICHUAN BAILI PHARMACEUTICAL CO. LTD.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 12 AUG 2022

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SYSTIMMUNE, INC.

Free format text: FORMER OWNER(S): BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.; SYSTIMMUNE, INC.